Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2024
2024-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The text specifically mentions Item 2.02, which is "Results of Operations and Financial Condition," and states that the company issued a press release announcing financial results for the quarter ended September 30, 2024. The document includes no detailed financial statements or substantive financial data itself but rather furnishes a press release as an exhibit. The document length is 7,759 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. According to the rules, a Form 8-K announcing quarterly financial results and furnishing a press release is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights only, not a comprehensive interim report (IR).
2024-11-07 English
S-8 POS
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to Form S-8 Registration Statement filed with the SEC. It relates to the registration of shares under the Securities Act of 1933 for stock incentive and employee stock purchase plans. The document includes consents from auditors and legal counsel, updates to exhibits, and signatures. It is a regulatory filing related to securities registration and amendments, not a financial report, earnings release, or management discussion. The document is not a report itself but an amendment to a registration statement, which fits the category of Regulatory Filings (RNS).
2024-08-08 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2024. The text explicitly states that the press release is being furnished as an exhibit and that the information is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is a current report announcing the earnings release rather than the earnings release itself. The document length is 3759 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release announcement (ER).
2024-08-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 25, 2024, by Werewolf Therapeutics, Inc. It reports initial results from a Phase 1 clinical trial and includes a press release as Exhibit 99.1. The document is a current report disclosing material events or corporate updates outside of regular periodic filings. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The content focuses on clinical trial results and a press release announcement, which fits the nature of a Regulatory Filing (RNS) as a general regulatory announcement and material event disclosure. The document length (10,256 characters) and content confirm it is a full Form 8-K filing, not merely a report publication announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-06-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.